Company News

UK’s CellCentric secures new investment

Wednesday 26 January 2022
Country
United Kingdom

UK-based CellCentric Ltd has secured a new investment from an arm of the American Cancer Society to progress a small molecule drug for multiple cancer indications. The investment, from BrightEdge, the cancer society’s philanthropic venture capital fund, will support clinical development of inobrodib, a candidate treatment for prostate and other cancers. Simultaneously, Morningside Investments Ltd, an existing investor, is increasing its financial support for the company. Both financing deals are equity investments, the size of which was not disclosed.

Imfinzi effective in advanced biliary tract cancer

Tuesday 25 January 2022
Country
United Kingdom

The checkpoint inhibitor Imfinzi (durvalumab), in combination with chemotherapy, reduced the risk of death by 20% in a Phase 3 trial of patients with advanced biliary tract cancer, the developer AstraZeneca Plc announced on 18 January. The multicentre trial compared Imfinzi and chemotherapy, with chemotherapy alone as a first-line treatment. Called TOPAZ-1, the trial enrolled 685 patients with unresectable cancer, including gallbladder cancer.

Keytruda improves survival for Asian liver cancer patients

Tuesday 25 January 2022
Country
United States

Asian patients with advanced hepatocellular carcinoma were able to live longer after being treated with Keytruda (pembrolizumab), one of the most widely prescribed checkpoint inhibitors for cancer. A Phase 3 trial of 453 patients with the disease achieved an overall survival rate of 21%, potentially acting as a confirmatory study for an accelerated approval given to Keytruda for this indication in the US, the developer Merck & Co Inc announced on 18 January.

Hal Barron to leave GSK for Altos Labs

Thursday 20 January 2022
Country
United States

Hal Barron, the chief scientific officer at GlaxoSmithKline Plc, is to become chief executive of a new regenerative medicine company that will seek to understand the process of cellular rejuvenation with the goal of slowing or even reversing the effects of disease. The company, Altos Labs Inc, will combine basic science with translational medicine across two institutes in the US and one in the UK. It is being launched with $3 billion of start-up capital, according to a statement issued on 19 January.

ReNeuron to focus on exosome platform

Thursday 20 January 2022
Country
United Kingdom

ReNeuron Group Plc has taken a decision to out-license a clinical-stage cell therapy programme for retinitis pigmentosa (RP), an eye disease in which the retina is damaged, and focus instead on developing its exosome technology. The decision was announced to the London Stock Exchange on 18 January.

UCB to acquire Zogenix

Thursday 20 January 2022
Country
Belgium

Belgium-based UCB SA is to acquire a US developer of drugs for rare diseases in a move that will both expand its existing epilepsy franchise and give it access to gene therapy technology. The proposed acquisition of Zogenix Inc of Emeryville, California is valued at approximately $1.9 billion (€1.7 billion) and has been approved by the boards of directors of both companies.

Hearing loss trial misses endpoint

Wednesday 19 January 2022
Country
France

A Phase 2 trial of a small molecule drug for the treatment of sudden sensorineural hearing loss, or sudden deafness, failed to meet its primary efficacy endpoint, the developer Sensorion SA, announced on 17 January. The drug, SENS-401, was safe and well-tolerated but did not show a significant improvement in pure tone audiometry, a test used to measure hearing sensitivity. In the trial, it was compared with a placebo and administered to patients over a period of four weeks. The trial, AUDIBLE-S, enrolled 115 patients.

Evotec and Lilly to research metabolic diseases

Wednesday 19 January 2022
Country
Germany

Evotec SE is to collaborate with Eli Lilly and Co to discover up to five potential therapeutics for diabetes and chronic kidney diseases, leveraging its experience in metabolic disease discovery to investigate new approaches. Evotec has already worked with Novo Nordisk A/S on possible treatments for kidney diseases and has access to a kidney disease patient database to identify and validate possible drug targets. In the field of diabetes, it has a proprietary beta cell replacement therapy in preclinical development.

GSK rejects bid for consumer unit

Monday 17 January 2022
Country
United Kingdom

GlaxoSmithKline Plc has confirmed media reports that it was approached three times by Unilever Plc to sell its joint venture consumer healthcare unit, but rejected the overtures. The most recent offer, made on 20 December 2021 was for £50 billion which would have comprised £41.7 billion in cash and £8.3 billion in Unilever shares. “GSK rejected all three proposals made on the basis that they fundamentally undervalued the consumer healthcare business and its future prospects,” the company said in a statement on 15 January 2022.

AZ partners with Scorpion Therapeutics

Sunday 16 January 2022
Country
United Kingdom

AstraZeneca Plc has agreed to pay $75 million initially, and up to an additional $1.5 billion in option fees and milestone payments, for rights to up to three small molecule therapeutics for cancer. The partner is Scorpion Therapeutics Inc of Boston, US, which has an integrated platform for drug discovery drawing on chemical proteomics, structure-based drug design and machine learning.